The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

PHASE3CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
DRUG

all-trans retinoic acid

ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.

DRUG

Eltrombopag

The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.

Trial Locations (5)

100010

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing

Unknown

Beijing Tongren hospital, Beijing

Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing

Department of Hematology, Beijing Hospital, Beijing

Department of Hematology, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Friendship Hospital

OTHER

collaborator

Beijing Tongren Hospital

OTHER

collaborator

Beijing Hospital

OTHER_GOV

collaborator

Navy General Hospital, Beijing

OTHER

lead

Peking University People's Hospital

OTHER